key: cord-0966843-unarx5bf
authors: Nawwar, Ayah Adel; Searle, Julie; Singh, Rajiv; Lyburn, Iain Douglas
title: Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT—not only an FDG finding
date: 2021-03-04
journal: Eur J Nucl Med Mol Imaging
DOI: 10.1007/s00259-021-05279-2
sha: e674958a50fecae8280fa7cf8ac7bddc64d1f2fb
doc_id: 966843
cord_uid: unarx5bf

nan

Large-scale worldwide COVID-19 vaccination programs are being rapidly deployed. Many patients with malignancy, a high-risk group, have recently had the first dose of the vaccine. A 75-year-old male with prostate cancer and biochemical recurrence underwent [18F]Choline PET/CT for disease assessment. No choline avid malignancy was identified; however, avid left axillary nodes were noted.

[18F]Choline PET/CT, maximal intensity projection (MIP)-A, demonstrates mild ill-defined uptake in the left arm (orange arrow) and areas of intense focal uptake in the left axilla (blue arrow). Tracer injection was via the right (contralateral) antecubital fossa, hence not a potential cause. The mildly avid symmetrical small volume mediastinal and hilar nodes are a common benign finding [1] . Axial CT, 

Ethics approval and informed consent All procedures performed involving the human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.

Competing interests The authors declare no competing interests.

18F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer

Imaging of COVID-19 vaccination at FDG PET/ CT